Celyad Oncology SA · EURONEXT:CYAD
Celyad Oncology SA — William Blair Growth Stock Conference 2020
23 slides from Celyad Oncology SA's conference presentation, October 2020

Slide 1: Corporate Presentation
Corporate Presentation William Blair Growth Stock Conference October 2020

Slide 2: Forward Looking Statements
Forward Looking Statements This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual

Slide 3: Celyad Oncology – Novel Perspective on CAR T Development
Celyad Oncology – Novel Perspective on CAR T Development Differentiation within Pioneer in Ahead of the Class in Robust Intellectual Allogeneic CAR T NKG2D CAR Ts Solid Tumors Property Estate • Leader in non-gene edited • Multiple NKG2D receptor- • CYAD-101 represents a • Nine foundational U.S. allo

Slide 4: Differentiated Pipeline of Next-Generation CAR T Candidates
Differentiated Pipeline of Next-Generation CAR T Candidates Allogeneic TARGET INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 CYAD-101 NKG2DL mCRC CYAD-103 NKG2DL Solid tumors CYAD-211 BCMA r/r MM CYAD-221 CD19 B-cell maligancies CYAD-231 NKG2DL x Solid tumors Undisclosed Autologous TARGET INDICATION

Slide 5: CYAD-101 – Allogeneic CAR T Candidate for mCRC
CYAD-101 – Allogeneic CAR T Candidate for mCRC

Slide 6: CYAD-101 – TIM-based Allogeneic CAR T Candidate for mCRC
CYAD-101 – TIM-based Allogeneic CAR T Candidate for mCRC Background on CYAD-101 • CYAD-101 co-expresses NKG2D receptor, novel allogeneic TCR Inhibitory Molecule (TIM) and selection marker • All-in-one vector approach • Single transduction • Avoids multiple genetic modifications and cost associated w

Slide 7: alloSHRINK Phase 1 Trial – Preliminary Results
alloSHRINK Phase 1 Trial – Preliminary Results Key Takeaways • Results demonstrate favorable tolerability profile for CYAD-101 with no DLT nor GvHD observed in fifteen patients from dose escalation • Best overall response includes two patients with partial response and two patients with durable stab

Slide 8: alloSHRINK Phase 1 Trial – Change in Tumor Burden From Baseline
alloSHRINK Phase 1 Trial – Change in Tumor Burden From Baseline RAS Mutated BRAF UNK UNK Wild-type Key Takeaways 40 PD • Tumor burden decrease was 30 observed in eight out of 15 PD evaluable patients, including six 20 PD(1) PD(1) SD of nine patients at dose level 3 10 SD % change from screening • Cl

Slide 9: CYAD-101 with KEYTRUDA® in Refractory mCRC
CYAD-101 with KEYTRUDA® in Refractory mCRC Background on KEYNOTE-B79 Trial • Recently announced clinical trial collaboration with MSD, a tradename of Merck & Co., Inc., to conduct the Phase 1b KEYNOTE-B79 clinical trial • KEYNOTE-B79 will evaluate CYAD-101 following FOLFIRI preconditioning chemother

Slide 10: Clinical Development of CYAD-101 – Summary
Clinical Development of CYAD-101 – Summary alloSHRINK KEYNOTE-B79 Future Trials • Encouraging initial data from • Evaluate CYAD-101 following • Opportunity to further assess CYAD-101 following FOLFOX FOLFIRI preconditioning CYAD-101’s potential clinical preconditioning chemotherapy chemotherapy, wit

Slide 11: CYAD-200 Series – shRNA-based Allogeneic Candidates
CYAD-200 Series – shRNA-based Allogeneic Candidates

Slide 12: shRNA Platform for Allogeneic CAR T Candidates
shRNA Platform for Allogeneic CAR T Candidates Developing a Next-Generation, Non-Gene Edited Allogeneic Platform • In 2018, the Company entered into an exclusive agreement with Horizon Discovery Group for the use of its shRNA SMARTVector technology to develop next-generation, non-gene edited allogen

Slide 13: CYAD-211 – Lead shRNA-based Allogeneic Candidate
CYAD-211 – Lead shRNA-based Allogeneic Candidate Expression of Single shRNA Hairpin Provides Prolonged TCR Knockdown • anti-BCMA CAR T cells with shRNA targeting CD3ζ component exhibit no signs of TCR activation with anti-tumor activity in preclinical models TCR Activation Graft-versus-Host Disease

Slide 14: CYAD-211 – anti-BCMA CAR-T for Multiple Myeloma
CYAD-211 – anti-BCMA CAR-T for Multiple Myeloma Background on IMMUNICY Phase 1 Trial • Open-label, Phase 1 dose-escalation trial to determine the recommended dose in multiple myeloma patients with relapsed or refractory disease • In addition, set to establish proof-of-concept using shRNA technology

Slide 15: shRNA Platform – Multiple Gene Knockdown
shRNA Platform – Multiple Gene Knockdown Efficient Expression of shRNAs Using All-in-One-Vector Approach • Duplex shRNA hairpin from a single vector enables generation of a homogenous CAR T cell population through single step enrichment Control Duplex shRNA CD3ζ + CD52 Duplex gRNA CD3ζ + CD52 gRNA:

Slide 16: shRNA Platform – Innovative Technology Offers Multiplex Capabilities
shRNA Platform – Innovative Technology Offers Multiplex Capabilities Single Multiplexed Vector Enables Knockdown of Four Genes Simultaneously • Transduced Jurkat cells demonstrate concurrent knockdown of the multiple gene products at the mRNA and protein levels mRNA Levels Protein Levels HLA-ABC CD3

Slide 17: CYAD-01 / CYAD-02 – Autologous AML / MDS Program
CYAD-01 / CYAD-02 – Autologous AML / MDS Program

Slide 18: Broad NKG2D Receptor CAR T r/r AML and MDS Program
Broad NKG2D Receptor CAR T r/r AML and MDS Program First-in-Class CYAD-01 Next-Generation CYAD-02 • Currently under investigation in ongoing • CYAD-02 leverages our shRNA technology to expansion cohort of Phase 1 THINK trial target the NKG2D ligands, MICA and MICB • THINK trial is assessing the safe

Slide 19: Strategy & Financials
elyad Oncology _ af Strategy & Financials

Slide 20: Strong Intellectual Property
Strong Intellectual Property Key U.S. Patents Strategic Validation • Allogeneic T-Cell Technology (1) • T cell receptor deficient T cell compositions • In May 2017, Celyad granted Novartis a • Method of producing T cell receptor non-exclusive license for allogeneic deficient T cells expressing a TCR

Slide 21: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones Second Half 2020 CYAD-101 in mCRC: Begin expansion cohort of alloSHRINK trial CYAD-211 in r/r MM: Initiate first-in-human, dose-escalation Phase 1 trial CYAD-01 in r/r AML and MDS: Report data from expansion cohort of Phase 1 THINK trial CYAD-02 in r/r AML and MDS: Re

Slide 22: Financial Snapshot
Financial Snapshot • Cash, cash equivalents and short-term investments of €26.7 million ($30.0 million) as of June 30, 2020 • Current cash expected to support the company’s activities into third quarter 2021 • Basic Shares Outstanding: 13.942 million • Ticker: Nasdaq (CYAD) and Euronext Brussels & P

Slide 23: Corporate Presentation
Corporate Presentation William Blair Growth Stock Conference October 2020
Source: Internet Archive copy of celyad.com





